<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913198</url>
  </required_header>
  <id_info>
    <org_study_id>CP4126-201</org_study_id>
    <nct_id>NCT00913198</nct_id>
  </id_info>
  <brief_title>A Study of CP-4126 in Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the biological activity of CP-4126 in patients&#xD;
      with advanced pancreatic cancer. In addition, the correlation between hENT1 (human&#xD;
      equilibrative nucleoside transporter 1) and overall survival will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological activity of CP-4126 in patients with advanced pancreatic cancer.</measure>
    <time_frame>Every second cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, Objective response rate.</measure>
    <time_frame>Every second cycle - study length</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Advanced Adenocarcinoma of Pancreas</condition>
  <arm_group>
    <arm_group_label>IV CP-4126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV CP-4126</intervention_name>
    <description>1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>IV CP-4126</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological confirmed advanced pancreatic cancer*&#xD;
&#xD;
          -  Not eligible for curative resection&#xD;
&#xD;
          -  Performance Status (ECOG) 0-2&#xD;
&#xD;
          -  Estimated life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate haematological and biological functions:&#xD;
&#xD;
               -  Neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets &gt; 100.0 x 109/L&#xD;
&#xD;
               -  Hb ≥ 10 g/dL&#xD;
&#xD;
               -  AST/ALT and alkaline phosphatase (ALP) ≤ 2.5 x institutional upper limit of&#xD;
                  normal (ULN), if liver metastases&#xD;
&#xD;
               -  AST/ALT ≤ 5 x institutional ULN and ALP ≤ 4 x institutional ULN&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times institutional ULN, if liver metastases ≤ 3 x institutional&#xD;
                  ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 times institutional ULN&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Participation in another therapeutic clinical study within 30 days of enrolment or&#xD;
             during this clinical study&#xD;
&#xD;
          -  Requirement of concomitant treatment with a non-permitted medication, including high&#xD;
             doses of vitamins and alternative drugs&#xD;
&#xD;
          -  History of allergic reactions to gemcitabine or egg&#xD;
&#xD;
          -  Presence of any serious concomitant systemic disorders incompatible with the clinical&#xD;
             study (e.g. uncontrolled inter-current illness including ongoing or active infection)&#xD;
&#xD;
          -  Presence of any significant central nervous system or psychiatric disorder(s) that&#xD;
             would hamper the patient's compliance&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Absence of adequate contraception for both male and female fertile patients for the&#xD;
             duration of the study; and also for three months after last treatment&#xD;
&#xD;
          -  Known positive status for HIV&#xD;
&#xD;
          -  Any reason why, in the investigator's opinion, the patient should not participate in&#xD;
             the study.&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Prior radical resection, but exploratory laparotomy as well palliative (e.g bypass)&#xD;
             surgery are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique d'Oncologie Médicale, Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, The Norwegian Radium Hospital,</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Ullevål</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Norway</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Advanced adenocarcinoma</keyword>
  <keyword>CP-4126</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

